帕博利珠单抗致慢性淋巴细胞白血病患者免疫性溶血性贫血，伊布替尼治疗有效。
Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib.
机构信息
Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
Division of Hematology, Oncology, and Stem Cell Transplant, Rush University Medical Center, Chicago, Illinois, USA.
出版信息
BMJ Case Rep. 2021 Sep 21;14(9):e245350. doi: 10.1136/bcr-2021-245350.
Abstract
We present a unique case of a patient with a long-standing history of indolent chronic lymphocytic leukaemia (CLL) who suddenly developed autoimmune haemolytic anaemia after starting immune checkpoint inhibitor therapy for bladder cancer. He had no clear indication to start CLL-directed treatment based on current clinical practice guidelines; however, targeted treatment of CLL with ibrutinib proved to be effective in treating the haemolytic anaemia.
摘要
我们报告了一例独特的病例，该患者患有慢性惰性淋巴细胞白血病（CLL）多年，在开始膀胱癌免疫检查点抑制剂治疗后突然发生自身免疫性溶血性贫血。根据当前的临床实践指南，他没有明确的指征开始针对 CLL 的治疗；然而，用伊布替尼对 CLL 进行靶向治疗证明对治疗溶血性贫血有效。
相似文献
1
Pembrolizumab-induced autoimmune haemolytic anemia in a patient with chronic lymphocytic leukaemia successfully treated with ibrutinib.
BMJ Case Rep. 2021 Sep 21;14(9):e245350. doi: 10.1136/bcr-2021-245350.
2
Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia.
Br J Haematol. 2016 Apr;173(2):326-7. doi: 10.1111/bjh.13602. Epub 2015 Jul 20.
3
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Br J Haematol. 2015 Sep;170(5):734-6. doi: 10.1111/bjh.13328. Epub 2015 Feb 25.
4
Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
Br J Haematol. 2021 Jan;192(1):e1-e4. doi: 10.1111/bjh.17105. Epub 2020 Oct 23.
5
Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.
Br J Haematol. 2016 Apr;173(2):327-8. doi: 10.1111/bjh.13601. Epub 2015 Jul 20.
6
Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
Br J Haematol. 1995 Oct;91(2):341-4. doi: 10.1111/j.1365-2141.1995.tb05300.x.
7
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
J Clin Exp Hematop. 2018 Sep 19;58(3):136-140. doi: 10.3960/jslrt.18012. Epub 2018 Jul 14.
8
Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
Ann Hematol. 2021 Nov;100(11):2861-2862. doi: 10.1007/s00277-021-04570-4. Epub 2021 Jun 10.
9
Fludarabine induced autoimmune haemolytic anaemia in a patient with chronic lymphocytic leukaemia.
J Pak Med Assoc. 2006 Jan;56(1):44-5.
10
Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy.
Leuk Res. 2016 Nov;50:31-36. doi: 10.1016/j.leukres.2016.09.002. Epub 2016 Sep 14.
引用本文的文献
1
Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review.
Front Immunol. 2025 Jul 3;16:1586426. doi: 10.3389/fimmu.2025.1586426. eCollection 2025.
2
Progress of research on PD-1/PD-L1 in leukemia.
Front Immunol. 2023 Sep 26;14:1265299. doi: 10.3389/fimmu.2023.1265299. eCollection 2023.
3
Evans syndrome during pembrolizumab therapy for upper urinary tract cancer.
IJU Case Rep. 2023 Jul 27;6(5):298-301. doi: 10.1002/iju5.12609. eCollection 2023 Sep.
本文引用的文献
1
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Front Immunol. 2020 Nov 18;11:594556. doi: 10.3389/fimmu.2020.594556. eCollection 2020.
2
Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
Thorac Cancer. 2020 Sep;11(9):2731-2735. doi: 10.1111/1759-7714.13582. Epub 2020 Aug 7.
3
[Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study].
Zhonghua Xue Ye Xue Za Zhi. 2020 May 14;41(5):412-416. doi: 10.3760/cma.j.issn.0253-2727.2020.05.009.
4
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
Thorac Cancer. 2020 Mar;11(3):799-804. doi: 10.1111/1759-7714.13281. Epub 2020 Feb 3.
5
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects.
Front Oncol. 2020 Jan 10;9:1435. doi: 10.3389/fonc.2019.01435. eCollection 2019.
6
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.
Cancers (Basel). 2020 Jan 23;12(2):282. doi: 10.3390/cancers12020282.
7
Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy - Interrupt or Continue Treatment - The Role of Immunohistochemical Examination.
Case Rep Oncol. 2019 Oct 29;12(3):820-828. doi: 10.1159/000504130. eCollection 2019 Sep-Dec.
8
AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report.
Case Rep Oncol. 2019 Jun 19;12(2):456-465. doi: 10.1159/000500856. eCollection 2019 May-Aug.
9
Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.
Blood Adv. 2019 Jun 25;3(12):1897-1906. doi: 10.1182/bloodadvances.2019000036.
10
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Am J Hematol. 2019 Jul;94(7):E183-E185. doi: 10.1002/ajh.25480. Epub 2019 Apr 11.
Zotero 插件